Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 10Ovarian Neoplasms 9Carcinoma, Ovarian Epithelial 8Neuroblastoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Myelodysplastic Syndromes 4Lung Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Acute 4Unspecified Adult Solid Tumor, Protocol Specific 3Sarcoma 3Polycythemia Vera 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Ganglioneuroblastoma 3Carcinoma, Non-Small-Cell Lung 3Anemia, Refractory, with Excess of Blasts 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Carcinoma, Neuroendocrine 2

Interventions

trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Letrozole 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cystadenocarcinoma, Serous × Topotecan × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡